Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy

Defining Early Human NK Cell Developmental Stages in Primary and Secondary Lymphoid Tissues

(2012) Diana N. Eissens et al.   PLoS One

CD48 as a novel molecular target for antibody therapy in multiple myeloma

(2011) Naoki Hosen et al.   BRITISH JOURNAL OF HAEMATOLOGY

Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity

(2010) C. J. Sanchez et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

(2010) R A Kyle et al.   LEUKEMIA

Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked

(2009) Marie von Lilienfeld-Toal et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G

(2008) G Maki et al.   LEUKEMIA